Back to results
US 11,441,187 B2Granted
Methods of characterizing and treating hidradenitis suppurativa
AssigneeThe George Washington University
InventorsVictoria Shanmugam, Derek Jones
Life of this patent
Estimating the term…
Abstract
Disclosures herein encompass methods of treating a subject with moderate to severe hidradenitis suppurativa (HS) encompassing the determination of differential gene expression to characterize HS severity followed by administration of a treatment specific for the stage of HS severity characterized in the subject.
Claims18
A method of treating a subject with moderate to severe hidradenitis suppurativa (HS), the method comprising:
- a) determining a gene expression level of S100A8, S100A9, NFATC3, dermcidin, and IL-37 in a biological sample of a human subject;
- b) characterizing HS severity by comparing the subject's gene expression levels of S100A8, S100A9, NFATC3, dermcidin, and IL-37 to a sample that does not have HS, wherein HS severity is characterized as moderate to severe when the expression level of at least S100A8, S100A9, and NFATC3, is increased in the subject compared to the sample that does not have HS, and
- the expression level of dermcidin or IL-37 is decreased in the subject compared to the sample that does not have HS;
- and
- c) administering an antibiotic, a retinoid, a steroid hormone, an anti-inflammatory, or a combination thereof to a subject characterized as having moderate to severe HS.
2 more elements
A method of treating a subject with moderate to severe hidradenitis suppurativa (HS), the method comprising:
- a) determining gene expression level of S100A8, S100A9, NFATC3, dermcidin, and IL-37 in a biological sample of a human subject;
- b) characterizing HS severity by comparing the subject's gene expression levels of S100A8, S100A9, NFATC3, dermcidin, and IL-37 to a sample that does not have HS,
- wherein HS severity is characterized as moderate to severe when the expression level of NFATC3 is increased at least 1.5-fold, the expression level of S100A8 is increased at least 2-fold and the expression level of S100A9 is increased at least 2-fold in the subject compared to the sample that does not have HS, and the expression level of dermcidin is decreased at least 3-fold and the expression level of IL-37 is decreased at least 2-fold in the subject compared to the sample that does not have HS;
- and
- c) administering an antibiotic, a retinoid, a steroid hormone, an anti-inflammatory, or a combination thereof to a subject characterized as having moderate to severe HS.
2 more elements
Dependencies are inferred from the claim text.